HIV / AIDS
EACS 2017: HIV Diagnoses in English Gay Men Have Been Falling Since 2014
- Details
- Category: HIV Prevention
- Published on Thursday, 09 November 2017 00:00
A new analysis by Public Health England of testing rates and HIV diagnoses from all of England’s sexual health clinics shows that the decline in diagnoses is England-wide, started at least a year before the decline was first noticed at London's 56 Dean Street clinic, and is not restricted to gay men who test frequently.
EACS 2017: High HIV Incidence from Non-Primary Partners and Low PEP and PrEP Use Seen in PARTNER Study
- Details
- Category: Treatment as Prevention
- Published on Tuesday, 07 November 2017 00:00
HIV incidence among the HIV-negative gay men in the PARTNER 1 and 2 studies, due to sex with partners outside their main relationship, was high, and very high among partners who admitted having condomless anal sex with non-primary partners, researchers reported at the recent 16th European AIDS Conference (EACS 2017) in Milan.
EACS 2017: Boosted Protease Inhibitor + Lamivudine Effective for HIV Maintenance Treatment
- Details
- Category: HIV Treatment
- Published on Tuesday, 31 October 2017 00:00
HIV maintenance treatment with 2 drugs, a boosted protease inhibitor and lamivudine, is just as effective as 3-drug treatment with a boosted protease inhibitor for people who already have fully suppressed viral load, according to a meta-analysis of clinical trials presented last weekat the 16th European AIDS Conference (EACS 2017) in Milan.
EACS 2017: Swiss Study Examines When Gay Men Decided to Stop Consistent Condom Use
- Details
- Category: HIV Sexual Transmission
- Published on Sunday, 05 November 2017 00:00
An innovative study presented at the 16th European AIDS Conference (EACS 2017) in Milan in October used a machine-learning algorithm (originally developed to help astronomers classify galaxies) to tease out whether there were specific groups of gay men within a large national cohort whose sexual risk behaviors followed similar trajectories over time, and if so, whether they were influenced by external factors such as new scientific data.
EACS 2017: ABX464 Reduces HIV Reservoir But Does Not Delay Vial Rebound
- Details
- Category: HIV Treatment
- Published on Tuesday, 31 October 2017 00:00
ABX464, a new drug that stimulates the clearance of HIV from infected cells, reduces the reservoir of HIV DNA in the body but does not delay the rebound of viral load when antiretroviral treatment is interrupted, Linos Vandekerckhove of the University of Ghent reported at the 16th European AIDS Conference (EACS 2017) last week in Milan.
EACS 2017: Survey of Dating App Users Finds that PrEP Usage Has Not Increased in Europe in the Last Year
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Thursday, 02 November 2017 00:00
A study of men who have sex with men (MSM) conducted by the European Centre for Disease Prevention and Control (ECDC) in collaboration with the gay contact site Hornet has found that pre-exposure prophylaxis (PrEP) usage has not increased, on average, among its respondents over the proportion reported last year, when a similar survey was carried out. The results were presented recently at the 16th European AIDS Conference (EACS 2017) in Milan.
EACS 2017: Symtuza as Effective as Multi-Pill Combination in Previously Untreated People with HIV
- Details
- Category: HIV Treatment
- Published on Sunday, 29 October 2017 00:00
The single-pill combination of darunavir, cobicistat, tenofovir alafenamide, and emtricitabine (Symtuza) is just as effective as a multi-pill combination of darunavir, cobicistat, emtricitabine, and the older tenofovir disoproxil fumarate formulation in previously untreated people with HIV, Chloe Orkin of the Royal London Hospital reported at the recet 16th European AIDS Conference (EACS 2017) in Milan.
More Articles...
- EACS 2017: How a London Clinic Reduced New HIV Infections by 90%
- IAS 2017: Why Curing Cancer May Be Like Curing HIV -- and May Be As Difficult
- IDWeek 2017: Long-Acting Monoclonal Antibody Effective Against Multidrug-Resistant HIV
- IDWeek 2017: Single-Tablet Protease Inhibitor Regimen Maintains Viral Suppression for a Year
- Virally Suppressed People Have "Effectively No Risk" of Transmitting HIV, Says CDC
Web Design and Development by